Search Results 41-50 of 16747 for Hodgkin disease
Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The main two subtypes are Hodgkin lymphoma and non-Hodgkin ...
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma ... Participant eligibility includes age, gender, type and stage of disease, ...
... Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine ... Participant eligibility includes age, gender, type and stage of disease, and ...
Immune blockade therapy isn't nearly as effective as a sole treatment for non-Hodgkin's lymphomas compared with Hodgkin's lymphoma. Mayo Clinic researchers see
Giving everolimus together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma. Participation eligibility. Participant eligibility includes ...
Biopsy-proven relapsed or refractory non-Hodgkin lymphoma or Hodgkin disease requiring treatment, who have failed, unable to tolerate, or refused other ...
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma ... disease, and previous ...
ROCHESTER, Minn. — A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma.
"CAR-T cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for patients who have relapsed or those who have not responded to prior ...
Clinical Trials · A Study to Evaluate the Effectiveness and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.